MedImmune Seeks Buyer

MedImmune Inc. (Nasdaq: MEDI) has retained Goldman Sachs to explore strategic alternatives that could include a sale of the company. The move comes after MedImmune received “indications of interest by major pharmaceutical companies, coupled with recent expressions by certain stockholders of dissatisfaction with the company's short-term stock price performance.” MedImmune's market cap was approximately $9 billion at market close yesterday.